# US 2021/0130307 A1 · Method for the manufacturing of delmopinol intermediates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0130307 A1
- Document ID: US20210130307A1
- Status: Published application
- Kind: A1
- Application number: 16/472,476
- Filed: 2017-12-20
- Published: 2021-05-06
- Earliest claimed: 2016-12-23
- Assignees: Lundbeck Pharmaceuticals Italy S.P.A.
- Applicants: Lundbeck Pharmaceuticals Italy S.p.A.
- Inventors: Carla De Faveri; Mariano Stivanello
- Web page: https://patentgrep.com/patent/US20210130307A1

## CPC

- C07D 265/30: not condensed with other rings
- B01J 23/42: Platinum
- B01J 23/44: Palladium
- C07C 17/16: of hydroxyl groups
- C07C 17/354: by hydrogenation
- C07C 21/04: Chloro-alkenes
- C07C 21/17: containing iodine
- C07C 29/36: increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal
- C07C 2601/02: with a three-membered ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention relates to a new process for producing intermediates useful in the manufacture of 2-(3-(4-propylheptyl)morpholino)ethan-1-ol. The invention also relates to intermediates 1-chloro-4-propylhept-3-ene and 1-iodo-4-propylhept-3-ene.

## Claims

### Claim 1

A process for manufacturing of delmopinol, which process comprises the use of 1-halo-4-propylhept-3-ene,
wherein said 1-halo-4-propylhept-3-ene (IV) is converted to 1-halo-4-propylheptane (V) by catalytic hydrogenation

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The process according to claim 1, wherein said catalytic hydrogenation takes place in an alcohol or an organic acid.

### Claim 4 (depends on 1)

The process according to claim 1, wherein said catalytic hydrogenation is performed with a catalyst selected from the group consisting of a palladium based catalyst and a platinum based catalyst.

### Claim 5 (depends on 1)

The process according to claim 1, wherein said catalytic hydrogenation is performed at a temperature from 20 to 60° C.

### Claim 6 (depends on 1)

The process according to claim 1, wherein said 1-halo-4-propylhept-3-ene (IV) is converted to 1-halo-4-propylheptane (V) by catalytic hydrogenation and wherein said 1-halo-propylheptane is subsequently converted to halomagnesiumpropylheptane, which is further reacted with oxazolidine[2,3-c]morpholine to obtain delmopinol
which is optionally followed by reaction with an appropriate acid to obtain a pharmaceutically acceptable salt of delmopinol.

### Claim 7 (depends on 1)

The process according to claim 1, wherein X is Cl.

### Claim 8 (depends on 1)

The process according to claim 1, wherein said 1-halo-4-propylhept-3-ene is prepared according to the process depicted below
wherein H+ is a halogenhydric acid (HX) or a non-halogenhydric acid.

### Claim 9

A process for the manufacture of 1-halo-4-propylhept-3-ene as depicted in the reaction scheme below
wherein H+ is a halogenhydric acid (HX) which is used in an amount of 1 to 2 equivalents relative to the cyclopropanecarbonyl derivative (I), or
wherein H+ is a non-halogenhydric acid used in an amount of 1 to 2.5 mol of acid per mol of 1-halomagnesiumpropane (II).

### Claim 10 (depends on 8)

The process according to claim 8, wherein R′ is —O-methyl.

### Claim 11 (depends on 8)

The process according to claim 8, wherein X is Cl.

### Claim 12 (depends on 8)

The process according to claim 8, wherein R′ is X′ and X′ is Cl.

### Claim 13 (depends on 8)

The process according to claim 8, wherein X″ is Cl or Br.

### Claim 14 (depends on 8)

The process according to claim 8, wherein 4-cyclopropylheptan-4-ol (III) is isolated from the reaction mixture prior to further processing and H+ is a halogenhydric acid.

### Claim 15 (depends on 8)

The process according to claim 8, wherein 4-cyclopropylheptan-4-ol (III) is not isolated from the reaction mixture prior to further processing, and wherein H+ is a non-halogenhydric acid.

### Claim 16 (depends on 15)

The process according to claim 15, wherein R═OAlk, and wherein the mixture of cyclopropanecarboxylic ester (I) and propylmagnesium halide (II) is treated with a non halogenhydric acid obtaining a 1-halo-propylhept-3-ene having the same halogen as the starting propylmagnesium halide (II).

### Claim 17 (depends on 15)

The process according to claim 15, wherein R═X′, and wherein X′═X″, and wherein the mixture of a cyclopropanecarbonyl halide (I) and propylmagnesium halide (II) is treated with a non halogenhydric acid giving 1-halopropylhept-3-ene having the same halogen as (I) and (II).

### Claim 18

The compound 1-chloro-4-propylhept-3-ene

### Claim 19

(canceled)

### Claim 20 (depends on 4)

The process according to claim 4, wherein said 1-halo-4-propylhept-3-ene (IV) is converted to 1-halo-4-propylheptane (V) by catalytic hydrogenation and wherein said 1-halo-propylheptane is subsequently converted to halomagnesiumpropylheptane, which is further reacted with oxazolidine[2,3-c]morpholine to obtain delmopinol
which is optionally followed by reaction with an appropriate acid to obtain a pharmaceutically acceptable salt of delmopinol.

### Claim 21 (depends on 4)

The process according to claim 4, wherein said 1-halo-4-propylhept-3-ene is prepared according to the process depicted below
wherein H+ is a halogenhydric acid (HX) or a non-halogenhydric acid.

### Claim 22 (depends on 5)

The process according to claim 5, wherein said catalytic hydrogenation is performed at a temperature from 30 to 40° C.
